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Abstract
Single-cell transcriptomics reveals gene expression heterogeneity but suffers from stochastic dropout and
characteristic bimodal expression distributions in which expression is either strongly non-zero or non-detectable.
We propose a two-part, generalized linear model for such bimodal data that parameterizes both of these features.
We argue that the cellular detection rate, the fraction of genes expressed in a cell, should be adjusted for as a
source of nuisance variation. Our model provides gene set enrichment analysis tailored to single-cell data. It
provides insights into how networks of co-expressed genes evolve across an experimental treatment. MAST is
available at https://github.com/RGLab/MAST.
Keywords: Bimodality, Cellular detection rate, Co-expression, Empirical Bayes, Generalized linear model, Gene set
enrichment analysis
Background
Whole transcriptome expression profiling of single cells
via RNA sequencing (scRNA-seq) is the logical apex to
single cell gene expression experiments. In contrast to
transcriptomic experiments on mRNA derived from bulk
samples, this technology provides powerful multi-
parametric measurements of gene co-expression at the
single-cell level. However, the development of equally
potent analytic tools has trailed the rapid advances in
biochemistry and molecular biology, and several challenges
need to be addressed to fully leverage the information in
single-cell expression profiles.
First, single-cell expression has repeatedly been shown
to exhibit a characteristic bimodal expression pattern,
wherein the expression of otherwise abundant genes is
either strongly positive or undetected within individual
cells. This is due in part to low starting quantities of
RNA such that many genes will be below the threshold
of detection, but there is also a biological component to
this variation (termed extrinsic noise in the literature)
that is conflated with the technical variability [1–3]. We
and other groups [4–7] have shown that the proportion
of cells with detectable expression reflects both technical
factors and biological differences between samples. Re-
sults from synthetic biology also support the notion that
bimodality can arise from the stochastic nature of gene
expression [2, 3, 8, 9].
Second, measuring single cell gene expression might
seem to obviate the need to normalize for starting RNA
quantities, but recent work shows that cells scale tran-
script copy number with cell volume (a factor that af-
fects gene expression globally) to maintain a constant
mRNA concentration and thus constant biochemical re-
action rates [10, 11]. In scRNA-seq, cells of varying vol-
ume, and hence mRNA copy number, are diluted to an
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approximately fixed reaction volume, leading to differ-
ences in detection rates of various mRNA species that
are driven by the initial cell volumes. Technical assay
variability (e.g., mRNA quality, pre-amplification effi-
ciency) and extrinsic biological factors (e.g., nuisance
biological variability due to cell size) that globally
affect transcription remain, and can significantly influ-
ence expression level measurements. Our approach
easily allows for estimation and control of the “cellular
detection rate” (CDR) while simultaneously estimating
treatment effects.
Previously, Kharchenko et al. [6] developed a so-called
three-component mixture model to test for differential
gene expression while accounting for bimodal expres-
sion. Their approach is limited to two-class comparisons
and cannot adjust for important biological covariates
such as multiple treatment groups and technical factors
such as batch or time information, limiting its utility in
more complex experimental designs. Several methods
have been proposed for modeling bulk RNA-seq data
that permit sophisticated modeling through linear [12]
or generalized linear models [13, 14], but these models
have not yet been adapted to single-cell data because
they do not properly account for the observed bimodal-
ity in expression levels. This is particularly important
when adjusting for covariates that might affect the ex-
pression rates. As we will demonstrate later, such model
mis-specification can significantly affect sensitivity and
specificity when detecting differentially expressed genes
and gene sets.
Here, we propose a hurdle model tailored to the ana-
lysis of scRNA-seq data, providing a mechanism to ad-
dress the challenges noted above. It is a two-part
generalized linear model that simultaneously models
the rate of expression over the background of various
transcripts, and the positive expression mean. Lever-
aging the established theory for generalized linear mod-
eling allows us to accommodate complex experimental
designs while controlling for covariates (including tech-
nical factors) in both the discrete and continuous parts
of the model. We introduce the CDR: the fraction of
genes that are detectably expressed in each cell. As dis-
cussed above, this acts as a proxy for both technical
(e.g., dropout, amplification efficiency) and biological
factors (e.g., cell volume and extrinsic factors other
than treatment of interest) that globally influence gene
expression. As a result, it represents an important
source of variability in scRNA-seq data that needs to be
modeled (Fig. 1). Our approach of modeling the CDR
as a covariate offers an alternative to the weight correc-
tion of Shalek et al. [5] that does not depend on the use
of control genes and allows us to jointly estimate nuis-
ance and treatment effects. Our framework permits the
analysis of complex experiments, such as repeated
single-cell measurements under various treatments or
longitudinal sampling of single cells from multiple sub-
jects with a variety of background characteristics (e.g.,
sex, age), because it can easily be extended to accom-
modate random effects. These features are especially
important when sampling single cells because there are
multiple sources of variance (e.g., cell-to-cell variance
within a subject, and subject-to-subject variance).
These type of experiments and designs will become
routine in future single-cell studies, such as for clinical
trials where single-cell assays will be performed on
large cohorts with complex designs.
In our hurdle model, differences between treatment
groups are summarized with pairs of regression coeffi-
cients whose sampling distributions are available through
bootstrap or asymptotic expressions, enabling us to per-
form complementary differential gene expression and
gene set enrichment analyses (GSEA). We use an empir-
ical Bayesian framework to regularize model parameters,
which helps improve inference for genes with sparse ex-
pression, much like what has been done for bulk gene
expression [15]. Our GSEA approach accounts for gene–
gene correlations, which is important for proper control
of type I errors [16]. This GSEA framework is particularly
useful for synthesizing observed gene-level differences
into statements about pathways or modules. Finally, our
model yields “single cell residuals” that can be manipu-
lated to interrogate cellular heterogeneity and gene–gene
correlations across cells and conditions. We have named
our approach MAST for “Model-based Analysis of Single-
cell Transcriptomics.”
We illustrate the method on two data sets. We first
apply our approach to an experiment comparing primary
human non-stimulated and cytokine-activated mucosal-
associated invariant T (MAIT) cells. MAST identifies
novel expression signatures of activation, and the single-
cell residuals produced by the model highlight a popula-
tion of MAIT cells showing partial activation but no
induction of effector function. We then illustrate the ap-
plication of MAST to a previously published complex
experiment studying temporal changes in murine bone
marrow-derived dendritic cells subjected to lipopolysac-
charide (LPS) stimulation. We both recapitulate the
findings of the original publication and describe add-
itional coordinated gene expression changes at the
single-cell level across time in LPS-stimulated myeloid
dendritic cells (mDC).
Results and discussion
Our MAST framework models single-cell gene expres-
sion using a two-part generalized linear model. One
component of MAST models the discrete expression
rate of each gene across cells, while the other compo-
nent models the conditional continuous expression level
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(conditional on the gene being expressed). We define
the CDR as the proportion of genes expressed in a single
cell.
The CDR for cell i is:
CDRi ¼ 1=N
XN
g¼1
zig ð1Þ
where zig is an indicator if gene g in cell i was expressed
above background. We consider the implications of set-
ting the background to zero, or alternately to a conser-
vatively estimated non-zero threshold (see Additional
file 1: Methods). The CDR is not sensitive to how the
background is defined, nor does it change substantially
when only putative control (housekeeping) genes are
used in the summation in equation 1. Our threshold-
ing approach does not adversely affect detection of
differentially expressed genes and serves to make the
continuous expression (Et > 0) more normal (Additional
file 1: Figure S1).
MAST can account for variation in the cellular
detection rate
The principal component analysis (PCA) shown in Fig. 1
demonstrates that the CDR (see “Methods”) is an im-
portant source of variability. It correlates strongly with
the second principal component (PC, Pearson’s rho =
0.76 grouped, 0.91 stimulated, 0.97 non-stimulated) in the
MAIT data set and with the first PC (rho = 0.92 grouped,
0.97 non-stimulated, 0.92 LPS (lipopolysaccharide), 0.89
PAM (synthetic triacylated lipopeptide), 0.92 PIC (viral-like
double-stranded RNA)) in the mDC data set. Given that we
observe larger CDR variability within treatment groups than
across groups, it is likely that the CDR is a nuisance factor.
This is further supported by the fact that the CDR calculated
using control (e.g., housekeeping) genes was highly corre-
lated with the CDR calculated over all genes (Additional
file 1: Figure S2). Its role as a principal source of variation
persisted across experiments (Figure 1).
We thus conjecture that CDR is a proxy for unobserved
nuisance factors that should be explicitly modeled. In par-
ticular, we suggest that the CDR captures variation in global
Fig. 1 Cellular detection rate correlates with the first two principal components of variation. The fraction of genes expressed, or cellular detection
rate (CDR) correlates mostly with the a,c) first principal component (PC) of variation in the myeloid dendritic cells (DC) data set and mostly with
the second PC in the b,d) mucosal-associated invariant T (MAIT) data set
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transcription rates due to differences in cell size (among
other factors) [11], as well as technical variation due to fac-
tors such as cell viability and efficiency in first strand synthe-
sis. Fortunately, MAST easily accommodates covariates,
such as the CDR, and more importantly allows joint, additive
modeling of them with other biological variables of interest,
with the effect of each covariate decomposed into its discrete
and continuous parts. Applying an analysis of deviance with
MAST (see “Methods”), we quantified the amount of vari-
ability that could be attributed to CDR. The CDR accounted
for 5.2 % of the deviance in the MAIT data set and 4.8 % in
the mDC data set for the average gene, and often much
more than that: it comprised more than 9 % of the deviance
in over 10 % of genes in both data sets, particularly for the
discrete component of the model (Additional file 1: Figure
S3). It should also be noted that the CDR deviance estimates
for many of the genes were comparable to (if not greater
than) the treatment deviance estimates. It is possible that the
CDR and treatment effects could be partially confounded,
for example, treated cells could become larger in volume.
We explored the effect of confounding between the CDR
and treatment effects on the MAST false positive rate in the
presence and absence of CDR control in the MAST model
(Additional file 1: Figure S4A, B). Controlling for CDR im-
proved the sensitivity and specificity of MAST in the pres-
ence of confounding, and did not negatively impact its
performance either in the absence of confounding or in the
absence of a CDR effect.
That CDR predicts expression levels contradicts the
model of independent expression between genes, be-
cause the level of expression (averaged across many
genes) would not affect the level in any given gene were
expression independent. It is especially important to ad-
just for CDR when testing for co-expression between
genes, or the apparent correlation between genes is
greatly inflated (see “Residual analysis identifies net-
works of co-expressed genes implicated in MAIT cell
activation”).
Finally, we investigated the relationship between our
approach and the weight correction of Shalek et al. [5]
and other technical bias correction approaches like Re-
move Unwanted Variation (RUV) and Surrogate Variable
Analysis (SVA; Additional file 1: Figure S5A, B) [17, 18].
We observed a strong linear relationship between the
CDR and the weights of Shalek et al. [5], as well as with
the first component of SVA and second component of
RUV. Thus, use of the CDR as a covariate can be seen
as a statistically rigorous way to correct for the dropout
biases of Shalek et al. [5], without the need to use con-
trol genes. More importantly, it provides the ability to
control for these biases while estimating treatment ef-
fects. Although CDR was correlated to the latent com-
ponents found via RUV or SVA in the data sets we
consider here (Additional file 1: Figure S5C), CDR has
the advantage of biological interpretability as a cellular
scaling factor.
Single-cell sequencing identifies a transcriptional profile
of MAIT cell activation
We applied MAST to our MAIT data set to identify genes
up-regulated or down-regulated by cytokine stimulation
while accounting for variation in the CDR (see
“Methods”). We detected 291 differentially expressed
genes, as opposed to 1413 when excluding CDR. To deter-
mine whether this was due to a change in ranking or sim-
ply a shift in significance, we compared the overlap
between the top n genes in both models (varying n from
100 to 1413), and found that, on average, 35 % (range 32–
38 %) of genes were excluded when CDR was modeled,
suggesting that inclusion of this variable allows global
changes in expression, manifest in the CDR, to be decom-
posed from local changes in expression. This was sup-
ported by gene ontology (GO) enrichment analysis
(Additional file 1: Figure S6) of these CDR-specific
genes (n = 539), where we saw no enrichment for
modules associated with the treatment of interest.
These CDR-specific GO terms (e.g., involvement of
regulation of RNA stability and protein folding) may
hint at the biology underlying differences in the CDR
that are not necessarily associated with treatment.
In order to assess the type-I error rate of our ap-
proach, we also applied MAST to identify differentially
expressed genes across random splits of the MAIT cells.
As expected, MAST did not detect any significant differ-
ences (Additional file 1: Figure S7A ,B), whereas DEseq
and edgeR, designed for bulk RNA-seq, detected a large
number of differentially expressed genes even at a strin-
gent nominal false discovery rate (FDR). SCDE, a single-
cell RNA-seq specific method, also had higher FDRs
than MAST. Permutation analysis demonstrated that the
null distribution of the MAST test statistic was well cali-
brated (Additional file 1: Figure S8A).
We examined the GO enrichment of genes detected
by limma, edgeR, DESeq, or SCDE but not MAST and
found that these sets generally lacked significant enrich-
ment for modules related to the treatment of interest
(Additional file 1: Figures S9–S12). MAST with CDR con-
trol also detected enrichment of immune-specific GO
terms at a higher rate than other methods (Additional file
1: Figure S13). MAST’s testing framework has better sen-
sitivity and specificity than these approaches. Among
models that do not adjust for CDR, SCDE performs rela-
tively well but trails MAST and limma, which can adjust
for CDR.
Figure 2a shows the single-cell expression (log2-tran-
scripts per million [TPM]) of the top 100 genes identi-
fied as differentially expressed between cytokine (IL18,
IL15, IL12)-stimulated and non-stimulated MAIT cells
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using MAST. Following stimulation with IL12, IL15, or
IL18, we observed increased expression in genes with
effector function, including interferon-γ (IFNG), granzyme-
B (GZMB) and a concomitant down-regulation of the AP-1
transcription factor network. Up-regulation of IFNG and
GZMB following cytokine stimulation has also been reported
in natural killer (NK), natural killer T-cells (NKT), and mem-
ory Tcells. CD69 is an early and only transient marker of ac-
tivation that can be induced by stimulation of the T cell
receptor or by cytokine signals. Its down-regulation at the
mRNA level after 24 h likely precedes subsequent protein-
level down-regulation [19–21].
We used these lists of up-regulated and down-regulated
genes to define a MAIT activation score that differentiates
between stimulated and non-stimulated MAITs as shown
in Fig. 2b. This yields a score for each cell, based on the
model fit and adjusting for nuisance factors (see
“Methods”), defined as the expected expression level
across genes in a module. The score differentiates stimu-
lated and non-stimulated cells, and demonstrates that the
stimulated MAIT population was more heterogeneous in
its expression phenotype. In particular, a few stimulated
MAIT cells (SC08, SC54, SC48, SC15, SC46, and SC61 in
Fig. 2a) exhibited low expression of IFNG response genes,
suggesting these cells did not fully activate despite stimu-
lation. Post-sort experiments via flow cytometry showed
that the sorted populations were over 99 % pure MAITs
(Additional file 1: Figure S14A), exhibited a change in
cell size upon stimulation (Additional file 1: Figure
S14B), and that up to 44 % of stimulated MAITs did not
express IFNG or GZMB following cytokine stimulation
(Additional file 1: Figure S14C). The non-responding
cells in the RNA-seq experiment likely correspond to
these non-responding cells from the flow cytometry ex-
periment, and the observed frequencies of these cells in
the RNA-seq and flow populations are consistent with
each other (probability of observing 6 or fewer non-
responding cells = 0.16 under binomial sampling). We
discuss this heterogeneity in a further section. Import-
antly, the lists of up-regulated and down-regulated
genes can be used to define gene sets for GSEA in order
to identify transcriptional changes related to MAIT acti-
vation in bulk experiments.
GSEA highlights pathways implicated in MAIT cell
activation
We used MAST to perform GSEA (see “Methods”) in the
MAIT data using the blood transcriptional modules of Li
et al. [22]. The cell-level scores for the top nine enriched
modules (Fig. 3a) continued to show significant heterogen-
eity in the stimulated and non-stimulated cells, particularly
for modules related to T-cell signaling, protein folding,
proteasome function, and the AP-1 transcription factor
network. Although the standard deviations of the module
scores were greater for stimulated than non-stimulated
cells in seven of the top nine enriched modules (Additional
file 1: Table S2), the magnitude of variability for stimulated
and non-stimulated cells was fairly similar. Enrichment in
BA
Fig. 2 Single-cell expression (log2-transcripts per million) of the top 100 genes identified as differentially expressed between cytokine (IL18, IL15,
IL12)-stimulated (purple) and non-stimulated (pink) MAIT cells using MAST (a). Partial residuals for up-regulated and down- regulated genes are
accumulated to yield an activation score (b), and this score suggests that the stimulated cells have a more heterogeneous response to stimulation
than do the non-stimulated cells
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stimulated cells and non-stimulated cells is displayed for
each module for the discrete and continuous components of
the model in Fig. 3b (see “Methods”), as well as a Z-score
combining the discrete and continuous parts. The enrich-
ment in the T-cell signaling module was driven by the in-
creased expression of IFNG, GZMB, IL2RA, IL2RB, and
TNFRSF9, five of the six genes in the module. Stimulated
cells also exhibited increased energy usage, translation, and
protein synthesis, while down-regulating genes were involved
in cell cycle growth and arrest (and other cell cycle related
modules). The down-regulation of cell cycle growth inhib-
ition genes indicates that IL12, IL15, and IL18 signals are suf-
ficient to prepare MAIT cells for cell proliferation.
Interestingly, we observed down-regulation of mRNA tran-
scripts from genes in the AP-1 transcription factor network.
This has been previously described in dendritic cells in re-
sponse to LPS stimulation [23] and, indeed, we observed this
effect in the mDC data set analyzed here (Additional file 1:
Fig. S15).
Our GSEA approach is more powerful than existing
methods for bulk RNA-seq data (Additional file 1: Figure
S16), and we discovered significantly enriched modules with
clear patterns of stimulation-induced changes that other
methods omit (Additional file 1: Figure S17). Two such
modules include the “T-cell surface signature” and “chaper-
onin mediated protein folding,” whose component genes
showed elevated expression in response to stimulation
(Additional file 1: Fig. S17A–D). These additional discover-
ies are not solely due to greater permissiveness in MAST.
We applied MAST to identify differentially expressed gene
sets across random partitions of the non-stimulated cells, to
examine its FDR. As expected, MAST did not detect any
significant differences, which suggests that it has good type I
error control (Additional file 1: Figure S7A).
Residual analysis identifies networks of co-expressed
genes implicated in MAIT cell activation
Much of the heterogeneity between the non-responding
and responding stimulated cells remained even after re-
moval of marginal (gene-level) stimulation effects. Given
that MAST models the expected expression value for
each cell, we can compute residuals adjusted for known
sources of variability (see “Methods”). The residuals can
be compared across genes to characterize cellular het-
erogeneity and correlation. We observed co-expression
in the residuals from stimulated cells that was not evi-
dent in the non-stimulated group (Fig. 4a, b). Because
the residuals removed any marginal changes due to
stimulation in each gene, the average residual in the two
groups is comparable. The co-expression observed,
meanwhile, is due to individual cells expressing these
genes dependently, where pairs of genes appear together
A B
Fig. 3 Module scores for individual cells for the top nine enriched modules (a) and decomposed Z-scores (b) for single-cell gene set enrichment
analysis in the MAIT data set, using the blood transcription modules (BTM) database. The distribution of module scores suggests heterogeneity
among individual cells with respect to different biological processes. Enrichment of modules in stimulated and non-stimulated cells is due to a
combination of differences in the discrete (proportion) and continuous (mean conditional expression) components of genes in modules. The
combined Z-score reflects the enrichment due to differences in the continuous and discrete components
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more often than expected under a model of independent
expression.
Two clusters of co-expressed genes stood out in the
residuals of the stimulated cells (Fig. 4b). These clusters
showed coordinated, early up-regulation of GZMB and
IFN-γ in response to stimulation in MAIT cells and a
concomitant decrease in CD69 expression, an early and
transient activation marker. PCA of the model residuals
highlighted the non-responsive stimulated MAIT cells
(Fig. 4c).
Accounting for the CDR reduced the background
correlation observed between genes (Additional file 1:
Figure S18), with nearly 25 % of pairwise correlations
decreasing after CDR correction. When the CDR was
included in the model, the number of differentially
expressed genes with significant correlations across
cells (FDR adjusted p-value < 1 %) decreased from 73
to 61 in the stimulated cells, and from 808 to 15 in
non-stimulated cells. This shows that adjusting for
CDR is also important for co-expression analyses be-
cause it reduces background co-expression attributable
to cell volume, which otherwise results in dense, un-
interpretable gene networks.
Residual analysis of MAIT non-responding stimulated cells
The hurdle model expression residuals identified six
MAIT cells that did not have a typical activated expres-
sion profile in response to stimulation (Figs 2 and 3).
The proportion of these cells detected in the scRNA-seq
experiment was consistent with what was detected in
the flow cytometry experiment. The cells exhibited lower
levels of IFNG and GZMB than activated cells (Additional
file 1: Figure S19A), but also exhibited decreased expres-
sion of AP-1 component genes FOS and FOSB, consistent
with other stimulated cells (Additional file 1: Figure S19B).
They did not produce IFNG or GZMB upon cytokine
stimulation and exhibited expression profiles intermediate
to non-stimulated and stimulated cells (Additional file 1:
Figure S19C).
Temporal expression patterns of mouse dendritic cell
maturation
Shalek et al. [5] analyzed murine bone marrow-derived
dendritic cells simulated using three pathogenic compo-
nents over the course of 6 h and estimated the propor-
tion of cells that expressed a gene and the expression
level of expressing cells. We compared results from ap-
plying our model to those obtained by Shalek et al. [5]
when analyzing their LPS-stimulated cells. As with the
MAIT analysis, we used MAST adjusting for the CDR.
MAST identified a total of 1359 differentially expressed
genes (1996 omitting the CDR), and the CDR accounted
for 5.2 % of the model deviance in the average gene.
The most significantly elevated genes at 6 h included
CCL5, CD40, IL12B, and interferon-inducible (IFIT) gene
family members, while down-regulation was observed for
EGR1 and EGR2, transcription factors that are known to
negatively regulate dendritic cell immunogenicity [24].
GSEA of mouse bone marrow-derived dendritic cells
We performed GSEA with the mouse GO modules and
three modules identified by Shalek et al. [5]. The blood
transcriptional modules of Li et al. [22] are shown in
Additional file 1: Figure S15. Figure 5 shows module
scores for significant GSEA modules for the LPS-
stimulated cells where the heatmap represents Z values
(see “Methods” for details). Besides finding signatures
consistent with the modules from Shalek et al. (Fig. 5a),
we identified modules that showed similar annotation
and overlap, significantly with the “core antiviral” and
A B C
Fig. 4 Gene–gene correlation (Pearson’s rho) of model residuals in non-stimulated (a) and stimulated (b) cells, and a principal components ana-
lysis biplot of model residuals (c) on both populations using the top 50 marginally differentially expressed genes. As marginal changes in the
genes attributable to stimulation and CDR have been removed, clustering of subpopulations in (c) indicates co-expression of the indicated genes
on a cellular basis. PC principal component
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“sustained inflammatory” signatures, including several
modules linked to type 1 interferon response and anti-
viral signatures (Fig. 5b). The “cellular response to
interferon-beta” signature (n = 22) overlapped with the
original core antiviral signature (n = 99) by 13 genes
(hypergeometric p = 1.24 × 10−23). The “response” and
“defense response to virus” signatures overlapped with
the core antiviral signature by 17 of 43 and 22 of 74
genes (hypergeometric p = 3.64 × 10−26 and 4.08 × 10−29,
respectively), suggesting the core antiviral signature cap-
tures elements of these known signatures. The “chemo-
kine” (n = 16) and “cytokine activity” (n = 51) modules
overlapped with the sustained inflammatory (n = 95) mod-
ule by 5 and 12 genes, respectively (hypergeometric p =
5.10 × 10−9 and 9.53 × 10−16). Our modeling approach
identified the two “early marcher” cells in the core anti-
viral module (marked with triangles on Fig. 5a) corre-
sponding to the same cells highlighted in figure 4b of
Shalek et al. [5]. Other modules exhibiting significant
time-dependent trends included a module of genes in-
volved in the AP-1 transcription factor network that was
down-regulated (Additional file 1: Figure S15), a finding
which has been previously shown in human monocytes
following LPS stimulation [23]. As with the MAITs, GSEA
permutation analysis to evaluate type I error rates did
not identify any significant modules (data not shown).
These results further confirm the original findings and
demonstrate the increased sensitivity of our approach.
GSEA heatmaps for the other stimulations can be found
in Additional file 1: Figure S20.
Residual analysis of mouse bone marrow-derived
dendritic cells identifies sets of co-expressed genes
We also explored stimulation-driven correlation pat-
terns. PCA (Fig. 6a) of the model residuals demonstrated
a clear time trend associated with PC1, as cells increase
Fig. 5 Module scores (a) and decomposed Z-scores (b) for single-cell gene set enrichment analysis for lipopolysaccharide (LPS)-stimulated
myeloid dendritic cells (mDC data set), using the mouse gene ontology (GO) biological process database. The change in single-cell module scores
over time for the nine most significantly enriched modules in response to LPS stimulation are shown in (a). The “core antiviral”, “peaked inflammatory,”
and “sustained inflammatory” modules are among the top enriched modules, consistent with the original publication. Additionally, we
identified the GO modules “cellular response to interferon-beta” and “response to virus,” which behave analogously to the core antiviral and
sustained inflammatory modules. No GO analog for the “peaked inflammatory” module was detected. The majority of modules detected
exhibited enrichment relative to the 1 h time point (thus increasing with time). The “early marcher” cells identified in the original publication
are highlighted here with triangles. We show the top 50 most significant modules (b). The combined Z-score summarizes the changes in the
discrete and continuous components of expression
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co-expression of interferon-activated genes. After re-
moving the marginal stimulation and adjusting for the
CDR, we observed correlation between chemokines
CCL5, TNF receptor CD40, and IFIT genes (Fig. 6b). A
principal finding of the original publication was the
identification of a subset of cells that exhibited an early
temporal response to LPS stimulation. Recapitulating
the original results here, when we examine the PCA of
the residuals using the genes in the core antiviral mod-
ule, we can identify the “early marcher” cells at the 1 h
time-point (Additional file 1: Figure S21). The co-
expression plot for other stimulations can be found in
the supplementary material (Additional file 1: Figures
S22 and 23).
Conclusion
We have presented MAST, a flexible statistical frame-
work for the analysis of scRNA-seq data. MAST is suit-
able for supervised analyses about differential expression
of genes and gene modules, as well as unsupervised ana-
lyses of model residuals, to generate hypotheses regarding
co-expression of genes. MASTaccounts for the bimodality
of single-cell data by jointly modeling rates of expression
(discrete) and positive mean expression (continuous)
values. Information from the discrete and continuous
parts is combined to infer changes in expression levels
using gene or gene set-based statistics. Because our ap-
proach uses a generalized linear framework, it can be used
to jointly estimate nuisance variation from biological and
technical sources, as well as biological effects of interest.
In particular, we have shown that it is important to control
for the proportion of genes detected in each cell, which
we refer to as the CDR, because this factor can single-
handedly explain 13 % of the variability in the 90 % per-
centile gene. Adjusting for CDR at least partially controls
for differences in abundance due to cell size and other ex-
trinsic biological and technical effects. Using several
scRNA-seq data sets, we showed that our approach pro-
vides a statistically rigorous improvement to methods pro-
posed by other groups in this context [5]. Although
MAST has greatest efficiency when the continuous (log)-
expression is normally distributed, transformations (such
as the Box-Cox) could also be applied if the non-zero con-
tinuous measurements are skewed.
As discussed by Padovan-Merhar et al. [11], care must
be taken when interpreting experiments where the sys-
tem shows global changes in CDR across treatment
groups. The question is essentially ontological: is the
CDR a mediator of the treatment effect (is it caused by
the treatment and intermediate to expression of the gene
* *
Fig. 6 Principal components analysis biplot of model residuals (a) and gene–gene correlation (Pearson’s rho) of model residuals (b) by time point
for lipopolysaccharide-induced myeloid dendritic cells (mDC data set) using 20 genes with the largest log-fold changes, given significant (false
discovery rate q < 0.01) marginal changes in expression. Principle component 1 (PC1) is correlated with change over time. The two “early marcher”
cells are highlighted by an asterisk at the 1 h time point. Correlation structure in the residuals is increasingly evident over time and can be clearly
observed at the 6 h time point compared to the earlier time points
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of interest), or does it confound the treatment effect
(does it happen to co-occur with treatment)? Regardless,
the CDR-adjusted treatment estimates are interpreted as
the change in expression due to treatment, if CDR were
held constant between the two conditions.
Two other alternative uses of the CDR are of note. It is
also possible to use CDR as a precision variable (an uncorre-
lated secondary cause) by centering the CDR within each
treatment groups, which makes the CDR measurement or-
thogonal to treatment. This would implicitly assume that
the observed changes are treatment induced, while still
modeling the heterogeneity in cell volume within each treat-
ment group. An alternative approach would be to estimate
the CDR coefficient using a set of control genes assumed to
be treatment invariant, such as housekeeping or ERCC
spike-ins [25, 26] and including it as an offset to the linear
predictors in the regression. An analogous approach is
undertaken by Buettner et. al. [26]. As noted by Hicks et al.
[27], the optimal approach to handle confounding between
technical and biological effects on the CDR is to design ex-
periments with biological replicates across multiple batches.
Finally, we note that while the methodology presented here
was developed using scRNA-seq data sets, it appears ap-
plicable to other single-cell gene expression platforms
where bimodal, conditionally normal expression patterns
are seen such as single-cell RNA-seq with unique molecu-
lar identifiers.
Methods
Data sets
Data for the MAIT study were derived from a single donor
who provided written informed consent for immune re-
sponse exploratory analyses. The study was approved by
the Fred Hutchinson Cancer Research Center institutional
review board.
MAIT cell isolation and stimulation
Cryopreserved peripheral blood mononuclear cells were
thawed and stained with Aqua Live/Dead Fixable Dead Cell
Stain and the following antibodies: CD3, CD8, CD4, CD161,
Vα7.2, CD56, and CD16. CD8+ MAIT cells were sorted as
live CD3+CD8+ CD4-CD161hiVα7.2+ cells and purity was
confirmed by post-sort fluorescence-activated cell sorting
analysis. Sorted MAIT cells were divided into aliquots and
immediately processed on a C1 Fluidigm (Fluidigm, South
San Francisco, CA) machine or treated with a combination
of IL-12 (eBioscience, San Diego, CA), IL-15 (eBioscience),
and IL-18 (MBL, Worburn, MA ) at 100 ng/mL for 24 h
followed by C1 processing.
C1 processing, sequencing, and alignment
After flow sorting, single cells were captured on the Flui-
digm C1 Single-Cell Auto Prep System (C1), lysed on
chip, and subjected to reverse transcription and cDNA
amplification using the SMARTer Ultra Low Input RNA
Kit for C1 System (Clontech, Mountain View, CA). Se-
quencing libraries were prepared using the Nextera XT
DNA Library Preparation Kit (Illumina, San Diego, CA)
according to C1 protocols (Fluidigm). Barcoded libraries
were pooled and quantified using a Qubit Fluorometer
(Thermo Scientific Life Technologies, Grand Island,
NY). Single-read sequencing of the pooled libraries was
carried out either on a HiScanSQ or a HiSeq2500 se-
quencer (Illumina) with 100-base reads, using TruSeq v3
Cluster and SBS kits (Illumina) with a target depth of
>2.5 M reads. Sequences were aligned to the UCSC Hu-
man Genome Assembly version 19, gene expression
levels quantified using RSEM [28], and TPM values
loaded into R [29] for analyses. See Additional file 1 for
more details on data processing procedures.
Time-series stimulation of mouse bone-marrow derived
dendritic cells
Processed RNA-seq data (TPM) were downloaded from
the Gene Expression Omnibus [GEO: GSE41265]. Align-
ment, pre-processing, and filtering steps have been pre-
viously described [5]. Low quality cells were filtered as
described in Shalek et al. [5].
Single-cell RNA-seq hurdle model
We model the log2(TPM+ 1) expression matrix as a two-
part generalized regression model. The gene expression rate
was modeled using logistic regression and, conditioning on
a cell expressing the gene, the expression level was modeled
as Gaussian.
Given normalized, possibly thresholded (see Additional
file 1), scRNA-seq expression Y = [yig], the rate of expression
and the level of expression for the expressed cells are mod-
eled conditionally independent for each gene g. Define the
indicator Z = [zig], indicating whether gene g is expressed in
cell i (i.e., zig= 0 if yig= 0 and zig= 1 if yig > 0). We fit logistic
regression models for the discrete variable Z and a Gaussian
linear model for the continuous variable (Y | Z= 1) inde-
pendently, as follows:
logit

PrðZig ¼ 1Þ
 ¼ Xi βDg
Pr Y ig ¼ yjZig ¼ 1
  ¼ N XiβCg ; σ2g
 
The regression coefficients of the discrete component are
regularized using a Bayesian approach as implemented in
the bayesglm function of the arm R package, which uses
weakly informative priors [30] to provide sensible estimates
under linear separation (See Additional file 1 for details).
We also perform regularization of the continuous model
variance parameter, as described below, which helps to in-
crease the robustness of gene-level differential expression
analysis when a gene is only expressed in a few cells.
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We define the CDR as the proportion of genes de-
tected in each cell. The CDR for cell i is:
CDRi ¼ 1=N
XN
g¼1
zig
An advantage of our approach is that it is straightfor-
ward to account for CDR variability by adding the vari-
able as a covariate in the discrete and continuous
models (column of the design matrix, X, defined above).
In the context of our hurdle model, inclusion of the
CDR covariate can be thought of as the discrete analog
of global normalization, and as we show in the examples,
this normalization yields more interpretable results and
helps decrease background correlation between genes,
which is desirable for detecting genuine gene co-
expression.
Shrinkage of the continuous variance
As the number of expressed cells varies from gene to
gene, so does the amount of information available to es-
timate the residual variance of the gene. However, many
genes can be expected to have similar variances. To ac-
commodate this feature of the assay, we shrink the gene-
specific variance estimates to a global estimate of the
variance using an empirical Bayes method. Let τg
2 be the
precision (1/variance) for Yg|Zg = 1 in gene g. We sup-
pose τg
2 ∼Gamma(α, β), find the joint likelihood (across
genes), and integrate out the gene-specific inverse vari-
ances. Then the maximum likelihood is used to estimate
α and β. Owing to conjugacy, these parameters are inter-
pretable, providing 2α pseudo-observations with preci-
sion β/α. This leads to a simple procedure where the
shrunken gene-specific precision is a convex combin-
ation of its maximum likelihood estimate (MLE) and the
common precision. This approach accounts for the fact
that the number of cells expressing a gene varies from
gene to gene. Genes with fewer expressed cells end up
with proportionally stronger shrinkage, as the ratio of
pseudo observations to actual observations is greater.
Further details are available in Additional file 1.
Testing for differential expression
Because Zg and Yg are defined conditionally independent
for each gene, tests with asymptotic χ2 null distributions,
such as the likelihood ratio or Wald tests, can be
summed and remain asymptotically χ2, with the degrees
of freedom of the component tests added. For the con-
tinuous part, we used the shrunken variance estimates
derived through our empirical Bayes approach described
above. The test results across genes can be combined
and adjusted for multiplicity using the FDR adjustment
[31]. In this paper, we declare a gene differentially
expressed if the FDR adjusted p-value is less than 0.01
and the estimated fold-change is greater than 1.5 (on a
log2 scale).
Gene set enrichment analysis
Our competitive GSEA compares the average model
coefficient in the test set (gene set of interest) to the
average model coefficient in the null set (everything
else) with a Z-test. Suppose the genes are sorted so
that the first G0 genes are in the null set, and the last
G −G0 genes are in the test set. Then, for example,
to test the continuous coefficients in the gene set, the
sample means of the coefficients in the test and null
sets are calculated, that is, calculate: θ^ ¼ 1= G−G0ð Þ
XG
g¼G0þ1β^g and θ^0 ¼ 1=G0
XG0
g¼1β^g . The sampling
variance of θ^0 , in principle, is equal to 1=G0
Xn
g¼1Var β^g
 
þ 2
X
1≤g<h<G0
Cov β^g ; ; β^h
  
, and
similarly for θ^ .
Given this sampling variance, a Z test can be formed
by comparing Z ¼ θ^−θ^0ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Var^ θ^ð ÞþVar^ θ^0ð Þ
p .
We estimate Var β^g
 
and Cov β^g ; β^h
 
via boot-
strap, to avoid relying on asymptotic approximations. In
practice, we found only a few (<100) bootstrap replicates
were necessary to provide stable variance-covariance es-
timates; however, even this modest requirement can be
relaxed for exploratory analysis by assuming independ-
ence across genes and using model-based (asymptotic)
estimates.
Z scores are formed and calculated equivalently for
the logistic regression coefficients. GSEA tests are done
separately on the two components of the hurdle model
and the results from the two components are combined
using Stouffer’s method [32], which favors consensus in
the two components [33] (see Additional file 1 for de-
tails). The approach is similar to that used by CAMERA
[16] for bulk experiments in its accounting for inter-
gene correlation that is known to inflate the false signifi-
cance (type-I error) in permutation-based GSEA proto-
cols [16], although it differs in that it uses the sampling
variance of each model coefficient to estimate the vari-
ance of the average coefficient, whereas CAMERA uses
the empirical variance of the model coefficients. In our
analyses, we used the Emory blood transcriptional mod-
ules [22] as well as mouse GO annotations available
from the Mouse Genome Informatics website [34].
GO enrichment analysis
Testing for enriched GO terms based on a list of genes
was performed with the GOrilla online tool by comparing
an unranked target list against a background list [35].
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Residual analysis
The hurdle model, in general, provides two residuals:
one for the discrete component and one for the continu-
ous component. Standardized deviance residuals are cal-
culated for the discrete and continuous component
separately, and then we combine the residuals by aver-
aging them. If a cell is unexpressed, then its residual is
missing and it is omitted from the average (details in
Additional file 1: Methods).
Module scores
In order to assess the degree to which each cell exhibits
enrichment for each gene module, we use quantities
available through our model to define module “scores,”
which are defined as the observed expression corrected
for CDR effect, analogous to those defined by Shalek
et al. [5]. The score sij for cell i and gene j is defined as
the observed expression corrected for the CDR effect:
sij = yij − ỹij where ỹij is the predicted effect from the fit-
ted model that excludes the treatment effects of interest.
This can be interpreted as correcting the observed ex-
pression of gene j in cell i by subtracting the condi-
tional expectation of nuisance effects. In our two part
model, ỹij = ẑijŷij , where ẑij and ŷij are the predicted
values from the discrete and continuous components
of our hurdle model.
A gene module score for cell i is the average of the
scores for the genes contained in the module, that is,
∑{j ∈ module}sij/|module|.
Availability of supporting data
MAST is available as an R package (http://www.github.
com/RGLab/MAST, doi: 10.5281/zenodo.18539), released
under the GPL license. All data and results presented in
this paper—including code to reproduce the results—are
available at: (http://github.com/RGLab/MASTdata/arch-
ive/v1.0.1.tar.gz, doi: 10.5281/zenodo.19041). Raw data
files have been submitted to NCBI’s sequence read archive
under project accession SRP059458.
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